Top Marijuana Stocks on the NASDAQ

Although the adulthood of U.S.-based cannabis companies and many foreign American Depository Receipts (ADRs) trade over the counter (OTC), a few marijuana throngs are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and neater spreads compared to the over-the-counter markets. For example, as the cannabis industry has grown in recent months and years, uplisting from an OTC furnish to a reputable U.S. exchange has become a banner achievement for many rising marijuana companies.

The NASDAQ was the first electronic exchange and has long been synonymous with technology and biotechnology. The cannabis throngs on the NASDAQ reflect this, and the majority of them operate in the biotech area of the industry. Here are the NASDAQ-listed marijuana genealogies, in alphabetical order, as of June 10, 2019, with a breakdown of their total returns.

Arena Pharmaceuticals is a biotech coterie involved in the manufacturing of medical marijuana drugs. Research and development around Arena’s APD371 is the primary focus of the unbending’s cannabis biotech initiatives.

Atlantic Alliance Partnership Corp. is a resourceless check company that is currently in a merger agreement with Kalyx Development Inc. Kalyx is a leading real development investment trust in the regulated cannabis industry in the United States.

Cara Therapeutics is a clinical-stage biotechnology company focused on blossom and commercializing new chemical entities for the indications of pain and pruritus (itching). Although all of the firm’s clinical-stage products target opioid receptors, Cara is currently acting preclinical research on cannabinoids for the treatment of neuropathic pain.

Corbus Pharmaceuticals Holdings Inc. is a cannabis biotech attendance. The group’s research, development, and manufacturing are based around cannabis drugs that seek to treat chronic, incendiary, fibrotic, and other diseases.

Cronos Group Inc. is a Canadian cannabis company. The series owns and seeks cannabis-related subsidiaries and licensed producers. In December of 2018, Marlboro maker Altria announced designs to invest $1.8 billion in Cronos. The investment has provided Cronos not only with additional cash to finance its sustained expansion but also with a well-established partner experienced in the marketing of consumer brands.

GW Pharmaceuticals is developing a portfolio of cannabinoid cure-alls. These medicines include Sativex for the treatment of spasticity related to multiple sclerosis and cancer pain and Epidiolex for the treatment of teens epilepsy. Sativex is commercialized in more than a dozen countries outside the United States and has received regulatory accept in several other countries. Epidiolex received FDA approval as a treatment for Dravet Syndrome and Lennox-Gastaut Syndrome, two forms of dire, early onset epilepsy without good existing treatment options. Other indications show that GW Pharmaceuticals is happening cannabinoid products for autism spectrum disorders, schizophrenia, and glioma.

Insys Correctives is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems. Although the suite is more widely known for its Subsys fentanyl spray, Insys has received FDA approval for a dronabinol (synthetic THC) oral denouement for the treatment of nausea caused by chemotherapy and anorexia in patients with AIDS. Insys is also developing cannabinoid-based treatments for epileptic disorders, Prader-Willi Syndrome (a genetic affection), and amphetamine addiction. On June 10, 2019, Bloomberg reported that Insys had filed for bankruptcy following lawsuits allied to its opioid-based drug Subsys.

Intec Pharma is a clinical-stage biopharmaceutical company that is expatiate on drugs based on its proprietary Accordion Pill technology. Intec’s product pipeline includes cannabinoid-based drugs for trim back pain and fibromyalgia.

New Age Beverages Corp. is a maker of beverages derived from yerba mate, green tea, kombucha, and similar products. In recent months, New Age has expanded its celebrate offerings to include CBD infusions as well, bringing it into the orbit of cannabis stocks.

Psychemedics Corporation serves in the enforcement sector. The company’s business operations support drug testing through hair samples.

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical fellowship focused on the development of cannabinoid-based drugs. Therapix’s current pipeline includes products targeted for the treatment of Tourette syndrome and warm cognitive impairment.

Tilray Inc. was the first marijuana-related company to have an initial public gift (IPO) in the United States. The Nanaimo, Vancouver Island-based company focuses on medical cannabis products.

Village Farms International is the most recent cannabis stock to begin trading on the NASDAQ. The company’s appropriations became available for trade on February 21, 2019. The company has a decades-long history in greenhouse produce production and has only recently shifted some of its heart toward cannabis production.

Zynerba Pharmaceuticals is focused on the development of synthetic cannabinoid treatments for transdermal (inclusive of the skin) delivery. Their pipeline currently includes two drugs being developed for indications including epilepsy, osteoarthritis, fibromyalgia, outer neuropathic pain, and Fragile X syndrome.